Combining IL-6 and SARS-CoV-2 RNAaemia-based risk stratification for fatal outcomes of COVID-19.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
01
2021
accepted:
29
07
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic rapidly increases the use of mechanical ventilation (MV). Such cases further require extracorporeal membrane oxygenation (ECMO) and have a high mortality. We aimed to identify prognostic biomarkers pathophysiologically reflecting future deterioration of COVID-19. Clinical, laboratory, and outcome data were collected from 102 patients with moderate to severe COVID-19. Interleukin (IL)-6 level and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA copy number in plasma were assessed with ELISA kit and quantitative PCR. Twelve patients died or required ECMO owing to acute respiratory distress syndrome despite the use of MV. Among various variables, a ratio of oxygen saturation to fraction of inspired oxygen (SpO2/FiO2), IL-6, and SARS-CoV-2 RNA on admission before intubation were strongly predictive of fatal outcomes after the MV use. Moreover, among these variables, combining SpO2/FiO2, IL-6, and SARS-CoV-2 RNA showed the highest accuracy (area under the curve: 0.934). In patients with low SpO2/FiO2 (< 261), fatal event-rate after the MV use at the 30-day was significantly higher in patients with high IL-6 (> 49 pg/mL) and SARS-CoV-2 RNAaemia (> 1.5 copies/μL) compared to those with high IL-6 or RNAaemia or without high IL-6 and RNAaemia (88% vs. 22% or 8%, log-rank test P = 0.0097 or P < 0.0001, respectively). Combining SpO2/FiO2 with high IL-6 and SARS-CoV-2 RNAaemia which reflect hyperinflammation and viral overload allows accurately and before intubation identifying COVID-19 patients at high risk for ECMO use or in-hospital death despite the use of MV.
Sections du résumé
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic rapidly increases the use of mechanical ventilation (MV). Such cases further require extracorporeal membrane oxygenation (ECMO) and have a high mortality.
OBJECTIVE
We aimed to identify prognostic biomarkers pathophysiologically reflecting future deterioration of COVID-19.
METHODS
Clinical, laboratory, and outcome data were collected from 102 patients with moderate to severe COVID-19. Interleukin (IL)-6 level and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA copy number in plasma were assessed with ELISA kit and quantitative PCR.
RESULTS
Twelve patients died or required ECMO owing to acute respiratory distress syndrome despite the use of MV. Among various variables, a ratio of oxygen saturation to fraction of inspired oxygen (SpO2/FiO2), IL-6, and SARS-CoV-2 RNA on admission before intubation were strongly predictive of fatal outcomes after the MV use. Moreover, among these variables, combining SpO2/FiO2, IL-6, and SARS-CoV-2 RNA showed the highest accuracy (area under the curve: 0.934). In patients with low SpO2/FiO2 (< 261), fatal event-rate after the MV use at the 30-day was significantly higher in patients with high IL-6 (> 49 pg/mL) and SARS-CoV-2 RNAaemia (> 1.5 copies/μL) compared to those with high IL-6 or RNAaemia or without high IL-6 and RNAaemia (88% vs. 22% or 8%, log-rank test P = 0.0097 or P < 0.0001, respectively).
CONCLUSIONS
Combining SpO2/FiO2 with high IL-6 and SARS-CoV-2 RNAaemia which reflect hyperinflammation and viral overload allows accurately and before intubation identifying COVID-19 patients at high risk for ECMO use or in-hospital death despite the use of MV.
Identifiants
pubmed: 34379684
doi: 10.1371/journal.pone.0256022
pii: PONE-D-21-00168
pmc: PMC8357172
doi:
Substances chimiques
Interleukin-6
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256022Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Lancet Respir Med. 2020 Nov;8(11):1066-1068
pubmed: 32798470
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8
pubmed: 33010257
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2575-2581.e2
pubmed: 32565226
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9
pubmed: 32710975
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Front Med (Lausanne). 2020 Oct 28;7:583897
pubmed: 33195334
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32544099
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174